ESMO 2021 | The role of the checkpoint inhibitors in breast cancer

Peter Schmid, MD, PhD, FRCP, Barts Cancer Institute, London, UK, discusses the role of checkpoint inhibitors in various subtypes of breast cancer. Checkpoint inhibitors play an important role in treating breast cancer, especially in metastatic PD-1-positive triple-negative breast cancer (TNBC). The results of trials including KEYNOTE-522 (NCT03036488) suggest checkpoint inhibitors can be the standard of care in multiple subtypes of breast cancer. Checkpoint inhibitors in the neoadjuvant setting additionally has been shown to be efficacious regardless of the PD-1 status of the patient. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.